MedTrace Logo

Open International Study on Quality of Life in Irritable Bowel Syndrome (IBS) Patients Before and After 8 Weeks Treatment With Mebeverine/Pinaverium Bromide

NCT01678781 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 607

Last updated 2013-09-09

No results posted yet for this study

Summary

A study to evaluate, by country and overall, the changes from baseline of the irritable bowel syndrome quality of life (IBS QoL) total score after 4 and 8 weeks of treatment with Duspatalin® or Dicetel® in IBS patients.

Conditions

  • Irritable Bowel Syndrome

Sponsors & Collaborators

  • CHILTERN International GmbH

    collaborator UNKNOWN

  • Abbott

    lead INDUSTRY

Principal Investigators

  • Guenter Krause · Abbott

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • China
  • Egypt
  • Mexico
  • Poland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01678781 on ClinicalTrials.gov